Cargando…

Milder disease with Omicron: is it the virus or the pre-existing immunity?

At the population level we are seeing milder disease during the Omicron wave of the SARS-CoV-2 pandemic. Is this due to the virus or pre-existing immunity, and what should we expect next?

Detalles Bibliográficos
Autor principal:	Sigal, Alex
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8767774/ https://www.ncbi.nlm.nih.gov/pubmed/35046570 http://dx.doi.org/10.1038/s41577-022-00678-4

Ejemplares similares

Omicron severity: milder but not mild
por: Nealon, Joshua, et al.
Publicado: (2022)

Omicron infection milder in nursing home residents
por: Katz, Morgan J, et al.
Publicado: (2022)

Estimating disease severity of Omicron and Delta SARS-CoV-2 infections
por: Sigal, Alex, et al.
Publicado: (2022)

Pre-existing immunity to SARS-CoV-2: the knowns and unknowns
por: Sette, Alessandro, et al.
Publicado: (2020)

Implications of COVID-19 for patients with pre-existing digestive diseases
por: Mao, Ren, et al.
Publicado: (2020)

Implications of COVID-19 for patients with pre-existing digestive diseases: an update
por: Mao, Ren, et al.
Publicado: (2021)

Omicron breakthrough infections in patients with immune-mediated inflammatory diseases
por: Liew, Jean W, et al.
Publicado: (2022)

Why is the SARS-CoV-2 Omicron variant milder?
por: Xia, Bingqing, et al.
Publicado: (2022)

SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases during the omicron dominant period
por: Boekel, Laura, et al.
Publicado: (2022)

Vaccination and protective immunity to SARS-CoV-2 omicron variants in people with immunodeficiencies
por: Nadesalingam, Angalee, et al.
Publicado: (2023)

Durability of AZD1222 and hybrid humoral immunity against omicron BA.1 and BA.4
por: Soto-Rifo, Ricardo
Publicado: (2023)

Omicron in pregnancy: time to breathe easier?
por: Auger, Nathalie, et al.
Publicado: (2022)

Prioritisation of COVID-19 boosters in the omicron era
por: Irving, Stephanie A, et al.
Publicado: (2022)

Milder COVID-19 in children with inborn errors of immunity
por: Yadav, Anjali, et al.
Publicado: (2022)

Omicron: fewer adverse outcomes come with new dangers
por: Post, Lori Ann, et al.
Publicado: (2022)

Effectiveness of mRNA booster doses against the omicron variant
por: Zedan, Hadeel T, et al.
Publicado: (2022)

Comment on van den Hurk et al. The Emergence of Japanese Encephalitis Virus in Australia in 2022: Existing Knowledge of Mosquito Vectors. Viruses 2022, 14, 1208
por: Brinkhoff, Michelle Nicole
Publicado: (2023)

COVID-19 vaccine boosters in the Asia-Pacific region in the context of Omicron
por: Hart, John D, et al.
Publicado: (2022)

Immune checkpoint inhibitors for patients with pre-existing autoimmune diseases
por: Maeda, Osamu
Publicado: (2023)

Online learning for WHO priority diseases with pandemic potential: evidence from existing courses and preparing for Disease X
por: Utunen, Heini, et al.
Publicado: (2023)

Pathogenicity of SARS-CoV-2 Omicron BA.1.1 in hamsters
por: Chan, Jasper Fuk-Woo, et al.
Publicado: (2022)

COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England
por: Kirsebom, Freja C M, et al.
Publicado: (2022)

The potential of Beta variant containing COVID booster vaccines for chasing Omicron in 2022
por: Sridhar, Saranya, et al.
Publicado: (2022)

SARS-CoV-2 spread and hospitalisations in paediatric patients during the omicron surge
por: Belay, Ermias D, et al.
Publicado: (2022)

Lower risk of Multi-system inflammatory syndrome in children (MIS-C) with the omicron variant
por: Lopez, Laura, et al.
Publicado: (2022)

The benefit of vaccination after previous SARS-CoV-2 infection in the omicron era
por: Boaventura, Viviane S, et al.
Publicado: (2023)

Bivalent omicron (BA.1) booster vaccination against SARS-CoV-2
por: Vasin, Andrey V, et al.
Publicado: (2023)

Could Beta variant containing COVID-19 booster vaccines tackle Omicron variants?
por: Jin, Pengfei, et al.
Publicado: (2023)

Boosting in the age of Omicron
por: Sigal, Alex
Publicado: (2023)

Extend existing food safety systems to the global wildlife trade
por: Biggs, Duan, et al.
Publicado: (2021)

Strengthening existing surveillance platforms to monitor pandemic-prone pathogens
por: Sylverken, Augustina Angelina
Publicado: (2023)

Pre-exposure anti-SARS-CoV-2 monoclonal antibodies in severely immunocompromised patients with immune-mediated inflammatory diseases
por: Goulenok, Tiphaine, et al.
Publicado: (2022)

SARS-CoV-2 in Malaysia: A surge of reinfection during the predominantly Omicron period
por: Yang, Su Lan, et al.
Publicado: (2022)

Neutralizing antibodies and their cocktails against SARS-CoV-2 Omicron and other circulating variants
por: Yang, Yang, et al.
Publicado: (2022)

Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic
por: Karim, Salim S Abdool, et al.
Publicado: (2021)

Co-existence of a pandemic (SARS-CoV-2) and an epidemic (Dengue virus) at some focal points in Southeast Asia: Pathogenic importance, preparedness, and strategy of tackling
por: Khan, Sakirul, et al.
Publicado: (2022)

New year, new SARS-CoV-2 variant: Resolutions on genomic surveillance protocols to face Omicron
por: Oróstica, Karen Y., et al.
Publicado: (2022)

Effectiveness of the COVID-19 vaccines against hospitalisation with Omicron sub-lineages BA.4 and BA.5 in England
por: Møller Kirsebom, Freja Cordelia, et al.
Publicado: (2022)

Immunity to Ebola virus: the full picture is being revealed
por: Etard, Jean-François
Publicado: (2021)

Is there any evidence for milder courses of monkeypox virus infections with childhood smallpox vaccination?
por: Hoffmann, Christian, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sikk0pidk5e3to7r2dkdbks0ri